Clinical Presentation, Treatment, and Outcome of Parathyroid Carcinoma: Results of the NEKAR Retrospective International Multicenter Study.
Journal
Annals of surgery
ISSN: 1528-1140
Titre abrégé: Ann Surg
Pays: United States
ID NLM: 0372354
Informations de publication
Date de publication:
01 02 2022
01 02 2022
Historique:
pubmed:
11
7
2020
medline:
19
2
2022
entrez:
11
7
2020
Statut:
ppublish
Résumé
In this retrospective cohort study, we describe the clinical presentation and workup of parathyroid carcinoma (PC) and determine its clinical prognostic parameters. Primary outcome was recurrence free survival. PC is an orphan malignancy for which diagnostic workup and treatment is not established. Eighty-three patients were diagnosed with PC between 1986 and 2018. Disease-specific and recurrence-free survivals were estimated with the Kaplan-Meier method. Risk factors for recurrence were identified by binary logistic regression with adjustment for age and sex. Thirty-nine tumors underwent central histopathological review. Renal (39.8%), gastrointestinal (24.1%), bone (22.9%), and psychiatric (19.3%) symptoms were the most common symptoms. Surgical treatment was heterogeneous [parathyroidectomy [PTx)] alone: 22.9%; PTx and hemithyroidectomy: 24.1%; en bloc resection 15.7%; others 37.3%] and complications of surgery were frequent (recurrent laryngeal nerve palsy 25.3%; hypoparathyroidism 6%). Recurrence of PC was observed in 32 of 83 cases. In univariate analysis, rate of recurrence was reduced when extended initial surgery had been performed (P = 0.04). In multivariate analysis low T status [odds ratio (OR) = 2.65, 95% confidence interval (CI) 1.02-6.88, P = 0.045], N0 stage at initial diagnosis (OR = 6.32, 95% CI 1.33-30.01, P = 0.02), Ki-67 <10% (OR = 14.07, 95% CI 2.09-94.9, P = 0.007), and postoperative biochemical remission (OR = 0.023, 95% CI 0.001-0.52, P = 0.018) were beneficial prognostic parameters for recurrence-free survival. Despite a favorable overall prognosis, PC shows high rates of recurrence leading to repeated surgery and postoperative recurrent laryngeal nerve palsy and hypoparathyroidism. In view of the reduced recurrence rate in cases of extended surgery, ipsilateral completion surgery may be considered when PC is confirmed.
Sections du résumé
OBJECTIVE
In this retrospective cohort study, we describe the clinical presentation and workup of parathyroid carcinoma (PC) and determine its clinical prognostic parameters. Primary outcome was recurrence free survival.
SUMMARY BACKGROUND DATA
PC is an orphan malignancy for which diagnostic workup and treatment is not established.
METHODS
Eighty-three patients were diagnosed with PC between 1986 and 2018. Disease-specific and recurrence-free survivals were estimated with the Kaplan-Meier method. Risk factors for recurrence were identified by binary logistic regression with adjustment for age and sex. Thirty-nine tumors underwent central histopathological review.
RESULTS
Renal (39.8%), gastrointestinal (24.1%), bone (22.9%), and psychiatric (19.3%) symptoms were the most common symptoms. Surgical treatment was heterogeneous [parathyroidectomy [PTx)] alone: 22.9%; PTx and hemithyroidectomy: 24.1%; en bloc resection 15.7%; others 37.3%] and complications of surgery were frequent (recurrent laryngeal nerve palsy 25.3%; hypoparathyroidism 6%). Recurrence of PC was observed in 32 of 83 cases. In univariate analysis, rate of recurrence was reduced when extended initial surgery had been performed (P = 0.04). In multivariate analysis low T status [odds ratio (OR) = 2.65, 95% confidence interval (CI) 1.02-6.88, P = 0.045], N0 stage at initial diagnosis (OR = 6.32, 95% CI 1.33-30.01, P = 0.02), Ki-67 <10% (OR = 14.07, 95% CI 2.09-94.9, P = 0.007), and postoperative biochemical remission (OR = 0.023, 95% CI 0.001-0.52, P = 0.018) were beneficial prognostic parameters for recurrence-free survival.
CONCLUSION
Despite a favorable overall prognosis, PC shows high rates of recurrence leading to repeated surgery and postoperative recurrent laryngeal nerve palsy and hypoparathyroidism. In view of the reduced recurrence rate in cases of extended surgery, ipsilateral completion surgery may be considered when PC is confirmed.
Identifiants
pubmed: 32649472
pii: 00000658-202202000-00055
doi: 10.1097/SLA.0000000000004144
doi:
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
e479-e487Informations de copyright
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest.
Références
Lee PK, Jarosek SL, Virnig BA, et al. Trends in the incidence and treatment of parathyroid cancer in the United States. Cancer 2007; 109:1736–1741.
Silva-Figueroa AM, Hess KR, Williams MD, et al. Prognostic scoring system to risk stratify parathyroid carcinoma. J Am Coll Surg 2017; 224:980–987.
Brown S, O’Neill C, Suliburk J, et al. Parathyroid carcinoma: increasing incidence and changing presentation. ANZ J Surg 2011; 81:528–532.
Wei CH, Harari A. Parathyroid carcinoma: update and guidelines for management. Curr Treat Options Oncol 2012; 13:11–23.
Schantz A, Castleman B. Parathyroid carcinoma. A study of 70 cases. Cancer 1973; 31:600–605.
Frank-Raue K, Haag C, Schulze E, et al. CDC73-related hereditary hyperparathyroidism: five new mutations and the clinical spectrum. Eur J Endocrinol 2011; 165:477–483.
Shaha AR, Shah JP. Parathyroid carcinoma: a diagnostic and therapeutic challenge. Cancer 1999; 86:378–380.
Talat N, Schulte KM. Clinical presentation, staging and long-term evolution of parathyroid cancer. Ann Surg Oncol 2010; 17:2156–2174.
Harari A, Waring A, Fernandez-Ranvier G, et al. Parathyroid carcinoma: a 43-year outcome and survival analysis. J Clin Endocrinol Metab 2011; 96:3679–3686.
Ferraro V, Sgaramella LI, Di Meo G, et al. Current concepts in parathyroid carcinoma: a single Centre experience. BMC Endocr Disord 2019; 19: (suppl 1): 46.
Young S, Wu JX, Li N, et al. More extensive surgery may not improve survival over parathyroidectomy alone in parathyroid carcinoma. Ann Surg Oncol 2016; 23:2898–2904.
Sadler C, Gow KW, Beierle EA, et al. Parathyroid carcinoma in more than 1,000 patients: a population-level analysis. Surgery 2014; 156:1622–1629. discussion 1629–1630.
Machens A, Lorenz K, Dralle H. Parathyroid hormone levels predict long-term outcome after operative management of parathyroid cancer. Horm Metab Res 2017; 49:485–492.
Ryhanen EM, Leijon H, Metso S, et al. A nationwide study on parathyroid carcinoma. Acta Oncol 2017; 56:991–1003.
Cetani F, Pardi E, Marcocci C. Update on parathyroid carcinoma. J Endocrinol Invest 2016; 39:595–606.
Evangelista L, Sorgato N, Torresan F, et al. FDG-PET/CT and parathyroid carcinoma: review of literature and illustrative case series. World J Clin Oncol 2011; 2:348–354.
Kemps B, van Ufford HQ, Creyghton W, et al. Brown tumors simulating metastases on FDG PET in a patient with parathyroid carcinoma. Eur J Nucl Med Mol Imaging 2008; 35:850.
Arslan N, Rydzewski B. Detection of a recurrent parathyroid carcinoma with FDG positron emission tomography. Clin Nucl Med 2002; 27:221–222.
Gardner CJ, Wieshmann H, Gosney J, et al. Localization of metastatic parathyroid carcinoma by 18F FDG PET scanning. J Clin Endocrinol Metab 2010; 95:4844–4845.
Lo WM, Good ML, Nilubol N, et al. Tumor size and presence of metastatic disease at diagnosis are associated with disease-specific survival in parathyroid carcinoma. Ann Surg Oncol 2018; 25:2535–2540.
Erickson LA, Jin L, Wollan P, et al. Parathyroid hyperplasia, adenomas, and carcinomas: differential expression of p27Kip1 protein. Am J Surg Pathol 1999; 23:288–295.
DeLellis RA. Parathyroid carcinoma: an overview. Adv Anat Pathol 2005; 12:53–61.
Stojadinovic A, Hoos A, Nissan A, et al. Parathyroid neoplasms: clinical, histopathological, and tissue microarray-based molecular analysis. Hum Pathol 2003; 34:54–64.
Wang O, Wang CY, Shi J, et al. Expression of Ki-67, galectin-3, fragile histidine triad, and parafibromin in malignant and benign parathyroid tumors. Chin Med J (Engl) 2012; 125:2895–2901.
Pyo JS, Cho WJ. Diagnostic and prognostic implications of parafibromin immunohistochemistry in parathyroid carcinomaT. Biosci Rep 2019; 39:
Wang P, Xue S, Wang S, et al. Clinical characteristics and treatment outcomes of parathyroid carcinoma: A retrospective review of 234 cases. Oncol Lett 2017; 14:7276–7282.
Salcuni AS, Cetani F, Guarnieri V, et al. Parathyroid carcinoma. Best Pract Res Clin Endocrinol Metab 2018; 32:877–889.
Karakas E, Muller HH, Lyadov VK, et al. Development of a formula to predict parathyroid carcinoma in patients with primary hyperparathyroidism. World J Surg 2012; 36:2605–2611.
Fendrich V, Waldmann J, Feldmann G, et al. Unique expression pattern of the EMT markers Snail, Twist and E-cadherin in benign and malignant parathyroid neoplasia. Eur J Endocrinol 2009; 160:695–703.
Kassahun WT, Jonas S. Focus on parathyroid carcinoma. Int J Surg 2011; 9:13–19.
Lefevre JH, Tresallet C, Leenhardt L, et al. Reoperative surgery for thyroid disease. Langenbecks Arch Surg 2007; 392:685–691.